A Phase II Randomized, Double Blind, Parallel Group, Placebo-Controlled Dose Finding and Efficacy Study of VPD-737 in the Treatment of Subjects With Chronic Pruritus

A study of a several doses of a novel treatment for chronic itch compared to placebo for patients whose condition has not responded to other treatments

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.

Investigator(s):

Intervention(s):

  • drug : Placebo
  • drug : VPD-737

Phase: Phase 2

Eligibility

Ages Eligible For Study:

18 Years - 65 Years

Inclusion Criteria

- Clinical diagnosis of chronic pruritus and unresponsive to current therapies

External Links

Contact information

Primary Contact:

Irene Bailey 650-721-7149

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: